A Prospective Evaluation of the Effect of Curcumin on Dose-limiting Toxicity and Pharmacokinetics of Irinotecan in Colorectal Cancer Patients

Trial Profile

A Prospective Evaluation of the Effect of Curcumin on Dose-limiting Toxicity and Pharmacokinetics of Irinotecan in Colorectal Cancer Patients

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Mar 2017

At a glance

  • Drugs Curcumin (Primary) ; Irinotecan (Primary)
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 17 Mar 2017 Planned End Date changed from 1 Jun 2020 to 5 Oct 2018.
    • 01 Jul 2016 Status changed from recruiting to active, no longer recruiting.
    • 08 Jun 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top